Today: 13 June 2026
Social Security COLA 2027 Estimate Ticks Up as Retirees Look at $77 More per Month
13 June 2026
1 min read

Social Security COLA 2027 Estimate Ticks Up as Retirees Look at $77 More per Month

Washington, June 12, 2026, 18:02 (ET)

  • The Senior Citizens League now sees the 2027 Social Security COLA at 3.8%. That’s above the 2.8% increase that went out in 2026.
  • The average monthly retirement benefit would rise by $77, moving from $2,026.41 to $2,103.41 with a 3.8% increase.
  • The 2027 COLA gets fixed after CPI-W numbers for the third quarter come out in October.

Social Security recipients could see a bigger boost to benefits in 2027 as fresh inflation numbers put upward pressure on the formula used for annual cost-of-living increases. The Senior Citizens League pegs the 2027 COLA at 3.8%. That’s a full point higher than the 2.8% raise that applied to 2026 checks.

A fresh estimate lands after the Bureau of Labor Statistics’ May inflation report. The Consumer Price Index for Urban Wage Earners and Clerical Workers, or CPI-W, climbed 0.7% in May, up 4.4% from a year ago. Broader CPI-U was up 0.5% last month and 4.2% over 12 months. Energy prices jumped 23.5% from a year earlier.

Retirees would see a bump in their monthly checks if the estimate sticks, but the gain would still be limited. For those getting the average retirement benefit of $2,026.41, a 3.8% COLA means about $77 more per month, bringing the typical payment to $2,103.41. That’s according to retirement industry reports citing The Senior Citizens League’s projection.

The final figure isn’t locked in yet. Social Security COLAs come from the average July, August and September CPI-W numbers versus last year’s same stretch, and then get rounded to the nearest tenth of a percent. May’s numbers move expectations, but they don’t decide the 2027 COLA itself.

There are also higher estimates. Mary Johnson, an independent analyst who covers Social Security and Medicare, is projecting the 2027 COLA might climb to 4.7% or above if inflation stays strong. She said inflation is putting “enormous cost pressures” on older Americans living on fixed incomes. NAPA

Social Security is the main income source for a big chunk of older Americans, so the latest numbers matter. A new Senior Citizens League survey out this week shows 44% of retirees—or about 24.8 million people—now rely completely on Social Security, up from 39% in 2025. TSCL Executive Director Shannon Benton said a 3.8% COLA “won’t be enough” to cover basics. NAPA

Investors tracking Social Security adjustments are waiting for the next inflation report, with the Bureau of Labor Statistics set to issue June CPI numbers on July 14. The official COLA comes later, after the September CPI-W in October, the agency said.

Social Security’s COLA outlook is expanding, while the program keeps facing questions about its finances. Trustees said this week the Old-Age and Survivors Insurance Trust Fund is expected to run out in the fourth quarter of 2032. After that, the program’s income would pay just 78% of promised benefits if Congress doesn’t step in.

Stock Market Today

  • Rezolve AI Plans $300 Million Buyback Amid Valuation Debate
    June 12, 2026, 6:08 PM EDT. Rezolve AI (RZLV) is under the spotlight after announcing a US$300 million share buyback funded from cash reserves. Trading at US$2.53, the stock gained 5.86% in one day but shows a 9.96% decline over 30 days. The company reaffirmed its 2026 revenue guidance and appointed a new Chief Marketing Officer, signaling confidence in growth. A popular market narrative values the stock at US$10.00, suggesting significant undervaluation, driven by potential recurring revenue growth and improved margins. However, risks around ambitious revenue targets and vendor integrations persist. Contrarily, some models, like Simply Wall St's discounted cash flow analysis, value the stock as low as US$0.15. Investors face a wide valuation gap, weighing Rezolve AI's future growth prospects against execution risks.

Latest articles

Alumis Shares Surge 16% as Traders Eye New Drug Move

Alumis Shares Surge 16% as Traders Eye New Drug Move

12 June 2026
Alumis soared 15.55% to $24.15 on double average volume after strong analyst support and late-stage psoriasis data, but remains a high-risk, loss-making biotech with no approved products; key investor focus is on Phase 2b lupus data due Q3 and a planned psoriasis NDA filing in Q4, with future stock moves hinging on these clinical and regulatory milestones.
The Trade Desk Stock Drops After Weak Q2 Outlook: Why TTD Investors Are Worried Now
Previous Story

Trade Desk shares bounce after dispute with Publicis resolves, but challenges remain for TTD

Go toTop